John Hussman's PHAT Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 84,000 shares of Phathom Pharmaceuticals, Inc. (PHAT) worth $933,240, representing 0.20% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, John Hussman has initiated a new position in PHAT, representing a fresh investment thesis on this company. Largest reduction occurred in Q1 2026, reducing 63,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Phathom Pharmaceuticals (PHAT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Phathom Pharmaceuticals (PHAT) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -63,000 | Reduce 42.86% | 84,000 | $11.11 |
| Q4 2025 | +147,000 | New Buy | 147,000 | $16.59 |
John Hussman's Phathom Pharmaceuticals Investment FAQs
John Hussman first purchased Phathom Pharmaceuticals, Inc. (PHAT) in Q4 2025, acquiring 147,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Phathom Pharmaceuticals, Inc. (PHAT) for 2 quarters since Q4 2025.
John Hussman's largest addition to Phathom Pharmaceuticals, Inc. (PHAT) was in Q4 2025, adding 147,000 shares worth $2.44 M.
According to the latest 13F filing for Q1 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 84,000 shares of Phathom Pharmaceuticals, Inc. (PHAT), valued at approximately $933,240.
As of the Q1 2026 filing, Phathom Pharmaceuticals, Inc. (PHAT) represents approximately 0.20% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Phathom Pharmaceuticals, Inc. (PHAT) was 147,000 shares, as reported at the end of Q4 2025.